{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T09:18:57Z","timestamp":1788686337047,"version":"build-2803163510"},"reference-count":57,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH COBRE","award":["P20GM121288"],"award-info":[{"award-number":["P20GM121288"]}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"crossref","award":["U54GM104940"],"award-info":[{"award-number":["U54GM104940"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"name":"LSU Health REP"},{"name":"NIH","award":["R01CA254197"],"award-info":[{"award-number":["R01CA254197"]}]},{"name":"NIH","award":["R01CA238514"],"award-info":[{"award-number":["R01CA238514"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with limited therapeutic options for patients at high risk of disease recurrence and metastasis. The cyclic nucleotide-degrading enzyme, phosphodiesterase 10A (PDE10), that hydrolyzes both cAMP and cGMP has been previously reported to be expressed in multiple cancers and regulates key cellular signaling pathways involved in cancer cell proliferation, survival, and maintenance of stem cell-like properties. We found that PDE10 overexpression was associated with poor relapse-free survival of TNBC patients and identified its potential as a therapeutic target for TNBC using a novel inhibitor, ADT-030. Our results showed that ADT-030 inhibited the growth of TNBC cells, reduced colony-forming efficiency and enhanced the therapeutic efficacy of paclitaxel. A TNBC mouse model demonstrated that oral administration of ADT-030 significantly suppressed syngeneic tumor growth and enhanced the antitumor efficacy of paclitaxel. ADT-030 treatment altered differentially expressed genes (DEGs), signaling pathways, and cellular processes. Overall, our findings suggest that ADT-030, as a monotherapy or in combination with standard-of-care chemotherapy, may be an effective therapeutic approach for TNBC. Further studies are warranted to better understand the oncogenic role of PDE10 in TNBC and the mechanisms by which ADT-030 modulates the tumor microenvironment (TME) and enhances chemotherapy response.<\/jats:p>","DOI":"10.3390\/cells15151374","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:09:42Z","timestamp":1785398982000},"page":"1374","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Developing a Phosphodiesterase 10A Inhibitor as a Novel Therapeutic Agent for Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"15","author":[{"given":"Mrityunjoy","family":"Biswas","sequence":"first","affiliation":[{"name":"Department of Genetics, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0912-7369","authenticated-orcid":false,"given":"Md","family":"Manirujjaman","sequence":"additional","affiliation":[{"name":"Department of Genetics, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovanny","family":"Zabaleta","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-6861","authenticated-orcid":false,"given":"Dorota","family":"Wyczechowska","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jone","family":"Garai","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-0798","authenticated-orcid":false,"given":"Qingzhao","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Public Health, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-9206","authenticated-orcid":false,"given":"Luis","family":"Del Valle","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"},{"name":"Department of Pathology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-664X","authenticated-orcid":false,"given":"Samarpan","family":"Majumder","sequence":"additional","affiliation":[{"name":"Department of Genetics, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kayes","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Keeton","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-7287","authenticated-orcid":false,"given":"Lucio","family":"Miele","sequence":"additional","affiliation":[{"name":"Department of Genetics, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"},{"name":"LSU-LCMC Health Cancer Center, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-4941","authenticated-orcid":false,"given":"Yulia Y.","family":"Maxuitenko","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4418-887X","authenticated-orcid":false,"given":"Gary A.","family":"Piazza","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fokhrul","family":"Hossain","sequence":"additional","affiliation":[{"name":"Department of Genetics, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"vi13","DOI":"10.1093\/annonc\/mds188","article-title":"Understanding the biology of triple-negative breast cancer","volume":"23","author":"Criscitiello","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumors","volume":"490","author":"Network","year":"2012","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1002\/cncr.27581","article-title":"Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014Expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e390464","DOI":"10.1200\/EDBK_390464","article-title":"Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between","volume":"43","author":"Han","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-10-0939","article-title":"Poly(ADP-Ribose) polymerase inhibition: \u201ctargeted\u201d therapy for triple-negative breast cancer","volume":"16","author":"Anders","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Obidiro, O., Battogtokh, G., and Akala, E.O. (2023). Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics, 15.","DOI":"10.20944\/preprints202306.0074.v1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/pcm-20-69","article-title":"A narrative review of chemotherapy in advanced triple negative breast cancer","volume":"4","author":"Pezo","year":"2021","journal-title":"Precis. Cancer Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lebedeva, V., Ebbinghaus, M., Hidalgo, J.V., Hardt, O., and Pfeifer, R. (2025). Triple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199714"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"69264","DOI":"10.18632\/oncotarget.20566","article-title":"Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking \u03b2-catenin and MAPK signaling","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13048-022-01050-9","article-title":"Phosphodiesterase 10A (PDE10A) as a novel target to suppress \u03b2-catenin and RAS signaling in epithelial ovarian cancer","volume":"15","author":"Borneman","year":"2022","journal-title":"J. Ovarian Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/onc.2014.94","article-title":"Phosphodiesterase 10A: A novel target for selective inhibition of colon tumor cell growth and \u03b2-catenin-dependent TCF transcriptional activity","volume":"34","author":"Li","year":"2015","journal-title":"Oncogene"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCRESAHA.122.322264","article-title":"PDE10A Inactivation Prevents Doxorubicin-Induced Cardiotoxicity and Tumor Growth","volume":"133","author":"Chen","year":"2023","journal-title":"Circ. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gazi, M.Y., Ye, Y., Okoko, O.D., Wang, X., Simon, S.E., Alimadadi, A., Suryawanshi, N., Brandle, C., Zheng, M., and Pei, L. (2026). Targeting phosphodiesterase 10A disrupts MAPK signaling pathways in the tumor microenvironment to unleash antitumor immunity. bioRxiv.","DOI":"10.64898\/2026.02.26.708383"},{"key":"ref_18","unstructured":"Bandi, D.S.R., Nagaraju, G.P., Sarvesh, S., Foote, J.B., Keeton, A.B., Chen, X., Ramirez-Alcantara, V., Holmes, T., Akce, M., and Singh, A. (2026). ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma. bioRxiv."},{"key":"ref_19","unstructured":"Piazza, G.A., Chen, X., Keeton, A.B., and Boyd, M.R. (2023). Indenyl Compounds, Pharmaceutical Compositions, and Medical Uses Thereof. (US 10,526,307 B2)."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hossain, F., Ucar, D.A., Monticone, G., Ran, Y., Majumder, S., Larter, K., Luu, H., Wyczechowska, D., Heidari, S., and Xu, K. (2023). Sulindac sulfide as a non-immune suppressive \u03b3-secretase modulator to target triple-negative breast cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1244159"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-1759(00)00231-3","article-title":"Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution","volume":"243","author":"Lyons","year":"2000","journal-title":"J. Immunol. Methods"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41523-025-00836-6","article-title":"Immunogenomic diversity of triple-negative breast cancers in obese and non-obese black and white women","volume":"11","author":"Hossain","year":"2025","journal-title":"npj Breast Cancer"},{"key":"ref_23","unstructured":"(2026, January 05). Kaplan-Meier Plotter. Available online: https:\/\/kmplot.com\/analysis\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1111\/bph.70215","article-title":"Pathway-level mutational signatures predict breast cancer outcomes and reveal therapeutic targets","volume":"182","author":"Posta","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"ref_26","first-page":"147","article-title":"TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer","volume":"11","author":"Chen","year":"2012","journal-title":"Cancer Inf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1101\/gad.351350.123","article-title":"Haploinsufficiency of phosphodiesterase 10A activates PI3K\/AKT signaling independent of PTEN to induce an aggressive glioma phenotype","volume":"38","author":"Nuechterlein","year":"2024","journal-title":"Genes Dev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/ijc.28449","article-title":"Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts","volume":"134","author":"Maenhout","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5416923","DOI":"10.1155\/2018\/5416923","article-title":"Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1002\/jcp.27740","article-title":"Cancer stem cells (CSCs) in cancer progression and therapy","volume":"234","author":"Najafi","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: Pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-025-02342-4","article-title":"Signaling pathways and targeted interventions for precancers","volume":"11","author":"Yang","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","article-title":"Triple-negative breast cancer therapeutic resistance: Where is the Achilles\u2019 heel?","volume":"497","author":"Bai","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Homayouni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Banerji","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/jnci\/djr246","article-title":"Opportunities and challenges in the development of experimental drug combinations for cancer","volume":"103","author":"Humphrey","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ghoflchi, S., Nakhaei, A., Abbasinezhad-Moud, F., Jalili-Nik, M., and Cimino, P.J. (2025). PDE10A as a novel diagnostic and therapeutic target in cancer: Insights and challenges. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1669157"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.canlet.2018.07.003","article-title":"Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model","volume":"433","author":"Karthikeyan","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rogers, M., Gill, D., Ahlqvist, E., Robinson, T., Mariosa, D., Johansson, M., Penha, R.C.C., Dossus, L., Gunter, M.J., and Moreno, V. (2022). Genetically-proxied impaired GIPR signalling and risk of 6 cancers. medRxiv.","DOI":"10.1101\/2022.08.06.22278459"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ncb2541","article-title":"Synaptotagmin-like proteins control the formation of a single apical membrane domain in epithelial cells","volume":"14","author":"Bryant","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cei\/uxab039","article-title":"Does CCL19 act as a double-edged sword in cancer development?","volume":"207","author":"Suksatan","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.jbior.2025.101116","article-title":"CD19 structure, expression, and signaling: From basic mechanisms to therapeutic targeting","volume":"99","author":"Schurmans","year":"2026","journal-title":"Adv. Biol. Regul."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/0008-5472.CAN-20-3773","article-title":"Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer","volume":"81","author":"Harris","year":"2021","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","article-title":"NF-\u03baB in inflammation and cancer","volume":"22","author":"Mao","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-\u03baB, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/omi.2017.0020","article-title":"NF-\u03baB Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers","volume":"21","author":"Poma","year":"2017","journal-title":"Omics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.12688\/f1000research.17023.1","article-title":"Tumour necrosis factor signalling in health and disease","volume":"8","author":"Holbrook","year":"2019","journal-title":"F1000Research"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Heimberger, A.B., Tripathi, S., and Platanias, L.C. (2023). Targeting Cytokines and Their Pathways for the Treatment of Cancer. Cancers, 15.","DOI":"10.3390\/cancers15215224"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes?","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10555-024-10206-6","article-title":"Tumor necrosis factor superfamily signaling: Life and death in cancer","volume":"43","author":"Ababneh","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"216642","DOI":"10.1016\/j.canlet.2024.216642","article-title":"Inhibition of ATM promotes PD-L1 expression by activating JNK\/c-Jun\/TNF-\u03b1 signaling axis in triple-negative breast cancer","volume":"586","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Popova, N.V., and J\u00fccker, M. (2022). The Functional Role of Extracellular Matrix Proteins in Cancer. Cancers, 14.","DOI":"10.3390\/cancers14010238"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40364-025-00757-3","article-title":"Extracellular matrix: Unlocking new avenues in cancer treatment","volume":"13","author":"Lee","year":"2025","journal-title":"Biomark. Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1374\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:34:01Z","timestamp":1785738841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":57,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15151374"],"URL":"https:\/\/doi.org\/10.3390\/cells15151374","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}